elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26852289-45999ECA-70F7-44BC-BBF5-8162D074F3CF
Q26852289-45999ECA-70F7-44BC-BBF5-8162D074F3CF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26852289-45999ECA-70F7-44BC-BBF5-8162D074F3CF
Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration
P2860
Q26852289-45999ECA-70F7-44BC-BBF5-8162D074F3CF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26852289-45999ECA-70F7-44BC-BBF5-8162D074F3CF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1400c9761fd40eae2c963b7e84199c936cb86363
P2860
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer